Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202409 · ClinicalTrials.gov registry record · Phase 2
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
A Phase 2 study of Gastrointestinal Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT01202409 is a Phase 2 study of Gastrointestinal Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants, below the 233-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01202409, a Phase 2 study of Gastrointestinal Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if panitumumab can help to control advanced cancer of the small bowel or ampulla of Vater. The safety of this drug will also be studied.
Conditions Studied
Interventions
- DRUG Panitumumab
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-11-02 |
| Est. Completion | 2018-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01202409
The ClinicalTrials.gov registry entry for NCT01202409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 233-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (92% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Panitumumab is the first listed.
NCT01202409 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01202409 about?
NCT01202409 is a clinical study titled "CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater". The goal of this clinical research study is to learn if panitumumab can help to control advanced cancer of the small bowel or ampulla of Vater. The safety of this drug will also be studied.
What is the current status of trial NCT01202409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2010-11-02. Estimated completion is 2018-07-03.
What conditions does trial NCT01202409 study?
This clinical trial studies the following conditions: Gastrointestinal Cancer.
What interventions are being tested in trial NCT01202409?
The interventions under investigation include: Panitumumab (DRUG).
Who is sponsoring clinical trial NCT01202409?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01202409 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
RECRUITING · Phase 2
-
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
RECRUITING · Phase 2
-
Avatrombopag vs. Placebo for CIT in GI Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.